Yamada Y, Miyagawa T, Toyoda H, Uesato K, Asanuma F, Ohsaku M, Kaneo K
Dept. of Surgery, Kitasato Institute Hospital.
Gan To Kagaku Ryoho. 2000 Nov;27(13):2139-43.
TS-1, a novel oral anticancer agent, was administered to a 68-year-old male patient with a paraaortic lymph node metastasis, 42 x 28 mm in size, of gastric cancer. The patient received four courses of treatment. Each treatment course consisted of a four-week administration followed by two drug-free weeks. The daily dose was 120 mg for the first two courses and 100 mg for the last two. A partial response was obtained after completion of the first course and a complete response was observed after the second. As of February, 2000, eleven months after the first administration, no regrowth of the tumor was observed either radiographically or by tumor marker levels. Adverse effects included stomatitis (grade 1), neutropenia (grade 3) and anemia (grade 1), all of which were temporary and needed no treatment. The patient's QOL improved gradually after the treatment. He is now in a good health and undergoes regular check-ups.
TS-1是一种新型口服抗癌药物，被用于治疗一名68岁的男性胃癌患者，该患者存在大小为42×28毫米的主动脉旁淋巴结转移。患者接受了四个疗程的治疗。每个疗程包括为期四周的给药期，随后是两周的无药期。前两个疗程的每日剂量为120毫克，后两个疗程为100毫克。第一个疗程结束后获得部分缓解，第二个疗程后观察到完全缓解。截至2000年2月，即首次给药后的11个月，影像学检查或肿瘤标志物水平均未观察到肿瘤复发。不良反应包括口腔炎（1级）、中性粒细胞减少（3级）和贫血（1级），所有这些均为暂时性，无需治疗。治疗后患者的生活质量逐渐改善。他目前身体健康，定期接受检查。
